

Special Issue

Multidrug Resistance in Cancer: Pharmacological Strategies

Message from the Guest Editor

Multidrug resistance is one of the major obstacles in current cancer treatment. Various mechanisms have been proposed for the development of drug resistance in cancers. To overcome the multidrug resistance in cancer treatment, small molecules, natural products, peptides, and nanotherapeutics have been developed in recent years. The most explored therapeutic target for combating multidrug resistance cancer is P-glycoprotein (P-gp), which belongs to the ABC transporter family. In addition, multidrug resistant cancer cells show selective sensitivity to some compounds. It has been proposed that P-gp-overexpressing cells are more sensitive to increased reactive oxygen species, to agents interfering the metabolic pathways related to cellular energy, and to alteration of membrane composition, and that they influence the elimination of endogenous toxic catabolites. However, the underlying mechanisms of collateral sensitivity have not been fully evaluated. This Special Issue welcomes studies, including original articles and reviews that investigate pharmacological strategies to overcome multidrug resistance in cancer treatment, ranging from basic research to clinical studies.

Guest Editor

Prof. Dr. Chin-Chuan Hung

Department of Pharmacy, College of Pharmacy, China Medical University, 91 Hsueh-Shih Road, Taichung 40402, Taiwan

Deadline for manuscript submissions

closed (31 December 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/108913

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)